CN1387887A - Chinese medicine prepn for treating arterioscleriosis - Google Patents
Chinese medicine prepn for treating arterioscleriosis Download PDFInfo
- Publication number
- CN1387887A CN1387887A CN02109860A CN02109860A CN1387887A CN 1387887 A CN1387887 A CN 1387887A CN 02109860 A CN02109860 A CN 02109860A CN 02109860 A CN02109860 A CN 02109860A CN 1387887 A CN1387887 A CN 1387887A
- Authority
- CN
- China
- Prior art keywords
- fructus
- chinese medicine
- carapax
- medicine preparation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The Chinese medicine preparation for treating arterioslerosis is prepared with rehmannia root, Chinese yam, privet fruit, mulberry, wolfberry fruit and other 12 kinds of Chinese medicinal material and through a scientific process. It has the functions of nourishing liver and kidney, softening dry feces, dissipating mass, promoting blood circulation to disperse blood clots, raising immunity, etc. It can cure arteriosclerosis radically and has less toxic side effect.
Description
Technical field:
The present invention relates to the medicine of arteriosclerosis disease, say it is to disclose the arteriosclerotic Chinese medicine preparation of a kind of treatment clearly, belong to traditional Chinese medical science pharmaceutical technology field.
Background technology:
Tremulous pulse medicated porridge sample (hereinafter to be referred as arteriosclerosis) is common clinical, frequently-occurring disease.At present, few for the Chinese Traditional Medicines of specially controlling arteriosclerosis disease, mainly contain medicines such as stasis is logical, evening primrose oil capsule, mainly be blood fat reducing, vessel softening alleviates some clinical symptoms, and curative effect is not fairly obvious.
Summary of the invention:
The present invention discloses the arteriosclerotic Chinese medicine preparation of a kind of treatment, eliminates arteriosclerotic mechanism of causing a disease, the enhancing human body immunity function, and clinical symptom disappearance is rapid, cures the no rebound phenomena in back.
The present invention is according to motherland's traditional Chinese medical science traditional theory, so that the kidney being the origin of congenital constitution, carry out vessel softening by replenishing the kidney(water)to nourish the liver(wood), the kidney invigorating nourishing the liver, selected pure Chinese herbal medicine with functions such as nourishing the liver and kidney, hard masses softening and resolving, activating blood circulation to dissipate blood stasis, raising immunologic functions, make pharmaceutical preparation through science, fundamentally treat arteriosclerosis.
Medicine of the present invention is the Chinese medicine preparation of being made by ratio of weight and the number of copies by following material:
The Radix Rehmanniae 15~25, Rhizoma Dioscoreae 15~25, Fructus Ligustri Lucidi 10~20, Fructus Mori 10~20, Fructus Lycii 15~25, Semen Plantaginis 10~20, Semen Cuscutae 18~25, Fructus Rubi 10~20, Poria 18~22, Cortex Moutan 18~20, Rhizoma Alismatis 8~15, Radix Salviae Miltiorrhizae 25~40, Os Draconis 20~25, Concha Ostreae 20~35, Concha Haliotidis 18~25, Carapax et Plastrum Testudinis 8~15, Carapax Trionycis 8~15.
Optimum ratio of the present invention is:
The Radix Rehmanniae 20, Rhizoma Dioscoreae 20, Fructus Ligustri Lucidi 15, Fructus Mori 15, Fructus Lycii 20, Semen Plantaginis 15, Semen Cuscutae 20, Fructus Rubi 15, Poria 20, Cortex Moutan 20, Rhizoma Alismatis 10, Radix Salviae Miltiorrhizae 30, Os Draconis 25, Concha Ostreae 25, Concha Haliotidis 20, Carapax et Plastrum Testudinis 10, Carapax Trionycis 10.
Processing procedure is as follows:
Take by weighing medicine according to the above ratio, with wherein 1/2nd be ground into fine powder, four times of water gagings of another false add decoct twice, each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20~1.25 (80~85 ℃), with above-mentioned fine powder mix homogeneously, xeraphium becomes fine powder, 120 orders sieve, and make the watered pill, are packaged into bag.
Above-mentioned medicament can be a said dosage form on any pharmaceutics.
Used in the present invention Chinese medicine, major part has the effect of nourishing the liver and kidney, vessel softening.Consider that arteriosclerosis mostly is the nephroyin and nephroyang loss of kidney, can not the unboiled water nourishing the liver, suffering from a deficiency of the kidney can not moistening venation, so added the invigorating the spleen and benefiting QI of being correlated with, the medicine of granulation promoting in the side.The deficiency of the Rhizoma Dioscoreae in the side, Rhizoma Alismatis, Radix Rehmanniae, Fructus Ligustri Lucidi, the special tonifying kidney-yin of Poria, and nourish edema with the liver involved, in case unit forms arteriosclerotic hypertension on the liver-yang.Fructus Schisandrae Chinensis, Fructus Lycii, Fructus Rubi, Semen Plantaginis, Semen Cuscutae specially can the kidney warming sun replenishing kidney-YIN.Medicines such as the Os Draconis that add, Concha Ostreae, Carapax et Plastrum Testudinis, Carapax Trionycis then can nourishing YIN for attracting YANG, suppressing the hyperactive liver to arrest the wind syndrome, the softening arteries of hard masses softening and resolving.Above-mentioned all medicines are harmonious, and play nourishing the liver and kidney, supplementing QI for promoting the production of body fluid, tranquillizing the mind by relieving convulsion, hard masses softening and resolving altogether, prevent and treat the effect of arteriosclerosis.
Cure mainly diseases such as the dizziness and tinnitus that arteriosclerosis, coronary heart disease, chronic nephritis, chronic hepatitis occur, weak limb fiber crops, pain in the lumbar region costalgia, shortness of breath and palpitation, forgetful, insomnia and dreamful sleep, dysphoria with feverish sensation in the chest palms and soles.
Usage and consumption: oral.Formulation rate of the present invention can be according to variations such as route of administration, patient age, body weight, disease type and the orders of severity, and daily dose is 10~16 grams.Each 5~7g, secondary took with eliminating cold for resuscitation water or yellow wine and to take after mixing it with water every day.
For showing the therapeutic effect of medicine of the present invention, select 413 routine tremulous pulse medicated porridge sample arteriosclerosis cases to take medicine of the present invention and observe, with 30 days be a course of treatment, carry out systems inspection respectively 2~3 courses of treatment, electrocardio, the Chest X-rays of X line, blood pressure, blood fat and examination of ocular fundus.
Curative effect determinate standard
1, cure: various symptoms all disappear.
2, produce effects: clinical symptoms and sign disappear or significantly improve situation: inspections such as blood pressure, blood fat, electrocardiogram recover normal or are clearly better.
3, improve: the more preceding improvement of clinical symptoms and sign, inspection indexs such as blood pressure, electrocardio, blood fat have improvement.
4, invalid: the more preceding nothing of objective indicators such as clinical symptoms sign, blood pressure, electrocardio, blood fat takes a turn for the better or increases the weight of.
5, to the judgement of hyperlipidemia curative effect: with cholesterol, triglyceride reduces by 20 milligrams below the %, the B-lipoprotein be reduced in 35 milligrams of following persons of % for effective.
6, to the judgement of hypertension curative effect: it serves as effective recovering normally or more originally to reduce by 10 millimetres of mercury persons with blood pressure.
Carrying out statistical analysis through system's clinical observation is summarized as follows:
Cure 242 examples in 413 routine patients, account for 58.6%, produce effects 12 examples account for 29.3%, improve 50 examples, account for 12.1%, total effective rate 87.9%.
Good effect of the present invention is: preparation is that pure Chinese herbal medicine is made, and is higher for the curative effect of arteriosclerosis, and treating both the principal and secondary aspects of a disease is evident in efficacy, has no adverse reaction, toxic and side effects is little, and clinical symptom disappearance is rapid, cures the no rebound phenomena in back.
The specific embodiment:
Embodiment 1
Take by weighing Radix Rehmanniae 20kg, Rhizoma Dioscoreae 20kg, Fructus Ligustri Lucidi 15kg, Fructus Mori 15kg, Fructus Lycii 20kg, Semen Plantaginis 15kg, Semen Cuscutae 20kg, Fructus Rubi 15kg, Poria 20kg, Cortex Moutan 20kg, Rhizoma Alismatis 10kg, Radix Salviae Miltiorrhizae 30kg, Os Draconis 25kg, Concha Ostreae 25kg, Concha Haliotidis 20kg, Carapax et Plastrum Testudinis 10kg, Carapax Trionycis 10kg, it is stand-by that 1/2nd of said medicine is ground into 120 purpose fine powders, four times of water gagings of another false add decoct twice, each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20~1.25 (80~85 ℃), with above-mentioned fine powder mix homogeneously, xeraphium becomes fine powder, 120 orders sieve, and make the soybean grain size watered pill, are packaged into bag.
Claims (3)
1, the arteriosclerotic Chinese medicine preparation of a kind of treatment is characterized in that being made by ratio of weight and the number of copies by following medicine:
The Radix Rehmanniae 15~25, Rhizoma Dioscoreae 15~25, Fructus Ligustri Lucidi 10~20, Fructus Mori 10~20,
Fructus Lycii 15~25, Semen Plantaginis 10~20, Semen Cuscutae 18~25, Fructus Rubi 10~20,
Poria 18~22, Cortex Moutan 18~20, Rhizoma Alismatis 8~15, Radix Salviae Miltiorrhizae 25~40, Os Draconis 20~25,
Concha Ostreae 20~35, Concha Haliotidis 18~25, Carapax et Plastrum Testudinis 8~15, Carapax Trionycis 8~15.
2, Chinese medicine preparation according to claim 1 is characterized in that optimum ratio is:
The Radix Rehmanniae 20, Rhizoma Dioscoreae 20, Fructus Ligustri Lucidi 15, Fructus Mori 15, Fructus Lycii 20, Semen Plantaginis 15, Semen Cuscutae 20, Fructus Rubi 15, Poria 20, Cortex Moutan 20, Rhizoma Alismatis 10, Radix Salviae Miltiorrhizae 30, Os Draconis 25, Concha Ostreae 25, Concha Haliotidis 20, Carapax et Plastrum Testudinis 10, Carapax Trionycis 10.
3,, it is characterized in that said medicament is a said dosage form on any pharmaceutics according to claim 1,2 described Chinese medicine preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021098603A CN1168473C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating arterioscleriosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021098603A CN1168473C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating arterioscleriosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1387887A true CN1387887A (en) | 2003-01-01 |
CN1168473C CN1168473C (en) | 2004-09-29 |
Family
ID=4740823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021098603A Expired - Fee Related CN1168473C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating arterioscleriosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1168473C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105535646A (en) * | 2016-01-28 | 2016-05-04 | 刘翠容 | Traditional Chinese medicine preparation for treating arteriosclerosis and preparation method of traditional Chinese medicine preparation |
CN107551088A (en) * | 2017-09-26 | 2018-01-09 | 覃益祥 | A kind of Chinese medicine composition to refresh the mind |
-
2002
- 2002-06-18 CN CNB021098603A patent/CN1168473C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105535646A (en) * | 2016-01-28 | 2016-05-04 | 刘翠容 | Traditional Chinese medicine preparation for treating arteriosclerosis and preparation method of traditional Chinese medicine preparation |
CN107551088A (en) * | 2017-09-26 | 2018-01-09 | 覃益祥 | A kind of Chinese medicine composition to refresh the mind |
Also Published As
Publication number | Publication date |
---|---|
CN1168473C (en) | 2004-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1047946C (en) | Preparation for treating senile diseases | |
CN102370949A (en) | Chinese medicinal compound preparation for treating cholecystitis and preparation method thereof | |
CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
CN101537093A (en) | Chinese traditional medicine for preventing and curing osteoporosis and preparation method thereof | |
CN1947786A (en) | Medicine for treating and preventing neurosis and its prepn. method | |
CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
CN1129130A (en) | Medicament for treatment of cervical spondylopathy | |
CN101757312A (en) | Chinese medicine preparation for treating thrombocytopenia | |
CN1279944C (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
CN1168473C (en) | Chinese medicine prepn for treating arterioscleriosis | |
CN101618131A (en) | Chinese medicinal compound preparation for treating coronary heart disease and angina | |
CN1324650A (en) | Effective medicine for treating cervical vertebra disease as one kind of intractable disease | |
CN1899482A (en) | Medicine for treating chronic glomerular nephritis and its producing method | |
CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
CN1814217A (en) | Chinese medicine composition for treating rheumatoid arthritis and use thereof | |
CN101129706A (en) | Traditional Chinese medicine formulated product for treating arteriosclerosis | |
CN103585414A (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter | |
CN1185007C (en) | Blood-lipid-reducing thrombolytic medicine | |
CN115252679B (en) | Traditional Chinese medicine composition for treating ischemic cardiomyopathy and application thereof | |
CN1076622C (en) | Chinese medicine for curing nephritis | |
CN1168472C (en) | Chinese medicine prepn for treating lupus erythematosus | |
CN1836705A (en) | Medicine for treating amblyopia and its preparing method | |
CN1168483C (en) | Heart disease treating medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |